124 related articles for article (PubMed ID: 23224745)
1. Immunohistochemistry of cytokeratins 7, 8, 17, 18, and 19, and GLUT-1 aids differentiation of desmoplastic malignant mesothelioma from fibrous pleuritis.
Horiuchi T; Ogata S; Tominaga S; Hiroi S; Kawahara K; Hebisawa A; Irei I; Ito I; Kameya T; Tsujimura T; Nakano T; Nakanishi K; Kawai T
Histol Histopathol; 2013 May; 28(5):663-70. PubMed ID: 23224745
[TBL] [Abstract][Full Text] [Related]
2. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma.
Kato Y; Tsuta K; Seki K; Maeshima AM; Watanabe S; Suzuki K; Asamura H; Tsuchiya R; Matsuno Y
Mod Pathol; 2007 Feb; 20(2):215-20. PubMed ID: 17192790
[TBL] [Abstract][Full Text] [Related]
4. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
[TBL] [Abstract][Full Text] [Related]
5. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining.
Mangano WE; Cagle PT; Churg A; Vollmer RT; Roggli VL
Am J Clin Pathol; 1998 Aug; 110(2):191-9. PubMed ID: 9704618
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
[TBL] [Abstract][Full Text] [Related]
7. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
Derakhshan F; Ionescu D; Cheung S; Churg A
Arch Pathol Lab Med; 2020 Feb; 144(2):185-188. PubMed ID: 31484000
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
9. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
[TBL] [Abstract][Full Text] [Related]
10. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
Kuperman M; Florence RR; Pantanowitz L; Visintainer PF; Cibas ES; Otis CN
Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
[TBL] [Abstract][Full Text] [Related]
11. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
Tot T
Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
[TBL] [Abstract][Full Text] [Related]
12. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
Lagana SM; Taub RN; Borczuk AC
Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
14. Diffuse malignant mesothelioma.
Oviedo SP; Cagle PT
Arch Pathol Lab Med; 2012 Aug; 136(8):882-8. PubMed ID: 22849735
[TBL] [Abstract][Full Text] [Related]
15. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
Piao ZH; Zhou XC; Chen JY
Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
[TBL] [Abstract][Full Text] [Related]
16. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
Miettinen M; Sarlomo-Rikala M
Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis.
Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF
Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250
[TBL] [Abstract][Full Text] [Related]
18. Utility of Site-Specific Biopsy for Diagnosis of Desmoplastic Malignant Mesothelioma.
Sakai T; Tane K; Usui Y; Miyoshi T; Matsumoto S; Aokage K; Goto K; Suzuki M; Ishii G; Tsuboi M
Ann Thorac Surg; 2018 Sep; 106(3):e125-e128. PubMed ID: 29601807
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of GLUT-1 in distinguishing malignant mesothelioma from reactive mesothelial cells: a meta-analysis.
Zhong SC; Ao XJ; Yu SH
Biomarkers; 2020 Mar; 25(2):157-163. PubMed ID: 31916460
[No Abstract] [Full Text] [Related]
20. Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.
Kushitani K; Amatya VJ; Mawas AS; Miyata Y; Okada M; Takeshima Y
Pathobiology; 2016; 83(1):33-40. PubMed ID: 26735863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
